{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:46:53Z","timestamp":1787244413607,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Regionala Forskningsr\u00e5det Uppsala-\u00d6rebro, Sweden","award":["grant numbers 651241, 842171, 930708"],"award-info":[{"award-number":["grant numbers 651241, 842171, 930708"]}]},{"name":"Regionala Forskningsr\u00e5det Uppsala-\u00d6rebro, Sweden","award":["grant numbers 651241, 842171, 930708"],"award-info":[{"award-number":["grant numbers 651241, 842171, 930708"]}]},{"name":"Regionala Forskningsr\u00e5det Uppsala-\u00d6rebro, Sweden","award":["grant numbers 651241, 842171, 930708"],"award-info":[{"award-number":["grant numbers 651241, 842171, 930708"]}]},{"name":"Region of V\u00e4rmland, Sweden","award":["grant numbers 637541, 741191, 840631, 930327, 939850, 967684, 980171, 993231"],"award-info":[{"award-number":["grant numbers 637541, 741191, 840631, 930327, 939850, 967684, 980171, 993231"]}]},{"name":"Erikssons foundation, Sweden","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Erikssons foundation, Sweden","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Erikssons foundation, Sweden","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Erikssons foundation, Sweden","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Selanders foundation","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Selanders foundation","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Selanders foundation","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Selanders foundation","award":["The relevant grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The relevant grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Region of Uppsala, Uppsala University Hospital \u2013 according to the ALF-agreement supporting the endocrine surgery research group","award":["The above mentioned grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The above mentioned grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Region of Uppsala, Uppsala University Hospital \u2013 according to the ALF-agreement supporting the endocrine surgery research group","award":["The above mentioned grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The above mentioned grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Region of Uppsala, Uppsala University Hospital \u2013 according to the ALF-agreement supporting the endocrine surgery research group","award":["The above mentioned grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The above mentioned grants to prof. Per Hellman have no designated numbers."]}]},{"name":"Region of Uppsala, Uppsala University Hospital \u2013 according to the ALF-agreement supporting the endocrine surgery research group","award":["The above mentioned grants to prof. Per Hellman have no designated numbers."],"award-info":[{"award-number":["The above mentioned grants to prof. Per Hellman have no designated numbers."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Primary aldosteronism (PA) is prevalent among hypertensive patients, and associated with worsened cardiovascular outcomes compared to essential hypertension (HT). Screening and diagnostics for PA are currently complicated and invasive, why new methods are needed. Unilateral PA (uPA) is best treated surgically, and bilateral PA (bPA) - medically. No validated proteomic diagnostic test has been found yet. Our aim was to explore proteomic markers in peripheral serum to discriminate between HT, PA, uPA and bPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-eight hypertensive individuals were evaluated for PA, and diagnosed with HT (n\u2009=\u200930); bPA (n\u2009=\u200929); and uPA (n\u2009=\u200929). Serum samples from these study groups were analyzed by Olink\u00ae Explore 384 Cardiometabolic Panel. A machine learning model based on ridge logistic regression with a stratified 5-fold cross-validation was used to identify HT, PA, bPA and uPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the study groups, 56 circulating proteins were significantly different, and some of them specifically: 4 between PA vs. HT; 3 between bPA vs. uPA; 1 between bPA vs. HT; 9 between uPA vs. HT; 1 between HT vs. bPA vs. uPA. Three proteins with strongest differentiation (Coagulation factor IX for PA vs. HT; dipeptidyl peptidase 4 for uPA vs. HT and bPA; heat shock protein B1 for bPA vs. uPA) were validated by enzyme-linked immunosorbent assay. Our machine learning model could successfully identify 95% of HT, bPA, and uPA samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum protein biomarkers may serve as a tool for discriminating HT, PA, uPA and bPA. Further studies are needed to support our results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-025-04302-y","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:24:17Z","timestamp":1749824657000},"page":"869-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Searching for peripheral proteomic markers of primary aldosteronism"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7866-677X","authenticated-orcid":false,"given":"Nikita","family":"Makhnov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Axling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Barazeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"St\u00e5lberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"\u00c5kerstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"no. 1","key":"4302_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone et al., Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6(no. 1), 41\u201350 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"no. 12","key":"4302_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ajh\/hpac079","volume":"35","author":"A Vaidya","year":"2022","unstructured":"A. Vaidya, G.L. Hundemer, K. Nanba, W.W. Parksook, J.M. Brown, Primary Aldosteronism: State-of-the-Art Review. Am. J. Hypertens. 35(no. 12), 967\u2013988 (2022). https:\/\/doi.org\/10.1093\/ajh\/hpac079.","journal-title":"Am. J. Hypertens."},{"issue":"no. 4","key":"4302_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M Naruse","year":"2022","unstructured":"M. Naruse et al., Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr. J. 69(no. 4), 327\u2013359 (2022). https:\/\/doi.org\/10.1507\/endocrj.EJ21-0508.","journal-title":"Endocr. J."},{"issue":"no. 6","key":"4302_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","volume":"39","author":"A Vaidya","year":"2018","unstructured":"A. Vaidya, P. Mulatero, R. Baudrand, G.K. Adler, The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr. Rev. 39(no. 6), 1057\u20131088 (2018). https:\/\/doi.org\/10.1210\/er.2018-00139.","journal-title":"Endocr. Rev."},{"issue":"no. 5","key":"4302_CR5","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder et al., The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(no. 5), 1889\u20131916 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4061.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"no. 1","key":"4302_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12020-022-03084-x","volume":"77","author":"J Ariens","year":"2022","unstructured":"J. Ariens, A.R. Horvath, J. Yang, K.W. Choy, Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism in primary care. Endocrine 77(no. 1), 11\u201320 (2022). https:\/\/doi.org\/10.1007\/s12020-022-03084-x.","journal-title":"Endocrine"},{"issue":"no. 8","key":"4302_CR7","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1210\/clinem\/dgab348","volume":"106","author":"A Hung","year":"2021","unstructured":"A. Hung et al., Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism. J. Clin. Endocrinol. Metab. 106(no. 8), 2423\u20132435 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab348.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"no. 4","key":"4302_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tcm.2021.03.005","volume":"32","author":"J Funder","year":"2022","unstructured":"J. Funder, Primary aldosteronism. Trends Cardiovasc. Med. 32(no. 4), 228\u2013233 (2022). https:\/\/doi.org\/10.1016\/j.tcm.2021.03.005.","journal-title":"Trends Cardiovasc. Med."},{"issue":"no. 9","key":"4302_CR9","doi-asserted-by":"publisher","first-page":"e3603","DOI":"10.1210\/clinem\/dgab327","volume":"106","author":"E Gkaniatsa","year":"2021","unstructured":"E. Gkaniatsa et al., Increasing incidence of primary aldosteronism in western sweden during 3 Decades \u2013 Yet an underdiagnosed disorder. J. Clin. Endocrinol. Metab. 106(no. 9), e3603\u2013e3610 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab327.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"no. 9","key":"4302_CR10","doi-asserted-by":"publisher","first-page":"e2016209","DOI":"10.1001\/jamanetworkopen.2020.16209","volume":"3","author":"G Eisenhofer","year":"2020","unstructured":"G. Eisenhofer et al., Use of steroid profiling combined with machine learning for identification and subtype classification in primary aldosteronism. JAMA Netw. Open 3(no. 9), e2016209 (2020). https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.16209.","journal-title":"JAMA Netw. Open"},{"key":"4302_CR11","doi-asserted-by":"publisher","unstructured":"Z. Erlic et al., Targeted metabolomics as a tool in discriminating endocrine from primary hypertension. J. Clin. Endocrinol. 106, 1111\u20131128 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa954.","DOI":"10.1210\/clinem\/dgaa954"},{"key":"4302_CR12","doi-asserted-by":"publisher","first-page":"104276","DOI":"10.1016\/j.ebiom.2022.104276","volume":"84","author":"PS Reel","year":"2022","unstructured":"P.S. Reel et al., Machine learning for classification of hypertension subtypes using multi-omics: a multi-centre, retrospective, data-driven study. eBioMedicine 84, 104276 (2022). https:\/\/doi.org\/10.1016\/j.ebiom.2022.104276.","journal-title":"eBioMedicine"},{"key":"4302_CR13","doi-asserted-by":"publisher","first-page":"e5855","DOI":"10.1002\/bmc.5855","volume":"38","author":"J Song","year":"2024","unstructured":"J. Song et al., Untargeted metabolomics reveals potential plasma biomarkers for diagnosis of primary aldosteronism using liquid chromatography\u2013mass spectrometry. Biomed. Chromatogr. 38, e5855 (2024). https:\/\/doi.org\/10.1002\/bmc.5855.","journal-title":"Biomed. Chromatogr."},{"issue":"no. 2","key":"4302_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/HYPERTENSIONAHA.118.11733","volume":"73","author":"MM Swierczynska","year":"2019","unstructured":"M.M. Swierczynska et al., Proteomic landscape of aldosterone-producing adenoma. Hypertension 73(no. 2), 469\u2013480 (2019). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11733.","journal-title":"Hypertension"},{"issue":"no. 5","key":"4302_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.122.20515","volume":"80","author":"L Ma","year":"2023","unstructured":"L. Ma et al., Phosphoproteomics reveals the wolframin-calcium axis as an important pathogenic signaling node in primary aldosteronism. Hypertension 80(no. 5), 995\u20131010 (2023). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.20515.","journal-title":"Hypertension"},{"issue":"no. 10","key":"4302_CR16","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1097\/HJH.0000000000001041","volume":"34","author":"H Remde","year":"2016","unstructured":"H. Remde et al., The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism. J. Hypertens. 34(no. 10), 2066\u20132073 (2016). https:\/\/doi.org\/10.1097\/HJH.0000000000001041.","journal-title":"J. Hypertens."},{"key":"4302_CR17","doi-asserted-by":"publisher","first-page":"768734","DOI":"10.3389\/fimmu.2021.768734","volume":"12","author":"CA Carvajal","year":"2021","unstructured":"C.A. Carvajal, A. Tapia-Castillo, J.A. P\u00e9rez, C.E. Fardella, Serum Alpha-1-acid glycoprotein-1 and urinary extracellular vesicle miR-21-5p as potential biomarkers of primary aldosteronism. Front. Immunol. 12, 768734 (2021). https:\/\/doi.org\/10.3389\/fimmu.2021.768734.","journal-title":"Front. Immunol."},{"key":"4302_CR18","doi-asserted-by":"publisher","unstructured":"F. Zhou et al., Targeted multiplex proteomics for the development and validation of biomarkers in primary aldosteronism subtyping. Eur. J. Endocrinol. 191, 558\u2013569 (2024). https:\/\/doi.org\/10.1093\/ejendo\/lvae148. lvae148.","DOI":"10.1093\/ejendo\/lvae148"},{"issue":"no. 2","key":"4302_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00259-022-05957-9","volume":"50","author":"I Silins","year":"2023","unstructured":"I. Silins et al., First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours. Eur. J. Nucl. Med. Mol. Imaging 50(no. 2), 398\u2013409 (2023). https:\/\/doi.org\/10.1007\/s00259-022-05957-9.","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"no. 1","key":"4302_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1210\/jc.2011-1537","volume":"97","author":"TJ Burton","year":"2012","unstructured":"T.J. Burton et al., Evaluation of the sensitivity and specificity of 11 C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s Adenomas. J. Clin. Endocrinol. Metab. 97(no. 1), 100\u2013109 (2012). https:\/\/doi.org\/10.1210\/jc.2011-1537.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"no. 1","key":"4302_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","volume":"29","author":"X Wu","year":"2023","unstructured":"X. Wu et al., [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat. Med. 29(no. 1), 190\u2013202 (2023). https:\/\/doi.org\/10.1038\/s41591-022-02114-5.","journal-title":"Nat. Med."},{"key":"4302_CR22","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.mcpro.2021.100168","volume":"20","author":"L Wik","year":"2021","unstructured":"L. Wik et al., Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol. Cell. Proteom. 20, 100168 (2021). https:\/\/doi.org\/10.1016\/j.mcpro.2021.100168.","journal-title":"Mol. Cell. Proteom."},{"issue":"no. 4","key":"4302_CR23","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"E. Assarsson et al., Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. PLoS ONE 9(no. 4), e95192 (2014). https:\/\/doi.org\/10.1371\/journal.pone.0095192.","journal-title":"PLoS ONE"},{"key":"4302_CR24","unstructured":"\u201cOlink Explore 3072\/384 \u2014 Olink\u00ae.\u201d Accessed: Nov. 29, 2024. [Online]. Available: https:\/\/olink.com\/products\/olink-explore-3072-384"},{"key":"4302_CR25","unstructured":"K. Nevola (kathy-nevola) et al., OlinkAnalyze: Facilitate Analysis of Proteomic Data from Olink. (Feb. 22, 2024). Accessed: Apr. 27, 2024. [Online]. Available: https:\/\/cran.r-project.org\/web\/packages\/OlinkAnalyze\/index.html"},{"key":"4302_CR26","doi-asserted-by":"publisher","unstructured":"M. Kuhn, \u201ccaret: Classification and Regression Training.\u201d p. 7.0\u20131, Oct. 05, (2007). https:\/\/doi.org\/10.32614\/CRAN.package.caret.","DOI":"10.32614\/CRAN.package.caret"},{"key":"4302_CR27","doi-asserted-by":"publisher","unstructured":"J. Friedman et al., \u201cglmnet: Lasso and Elastic-Net Regularized Generalized Linear Models.\u201d p. 4.1-8, (2008). https:\/\/doi.org\/10.32614\/CRAN.package.glmnet","DOI":"10.32614\/CRAN.package.glmnet"},{"issue":"no. 6","key":"4302_CR28","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/ejn.16226","volume":"59","author":"BI Arioz","year":"2024","unstructured":"B.I. Arioz, A. Cotuk, E.C. Yaka, S. Genc, Proximity extension assay-based proteomics studies in neurodegenerative disorders and multiple sclerosis. Eur. J. Neurosci. 59(no. 6), 1348\u20131358 (2024). https:\/\/doi.org\/10.1111\/ejn.16226.","journal-title":"Eur. J. Neurosci."},{"key":"4302_CR29","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.mcpro.2021.100155","volume":"20","author":"AH Ren","year":"2021","unstructured":"A.H. Ren, E.P. Diamandis, V. Kulasingam, Uncovering the depths of the human proteome: antibody-based technologies for ultrasensitive multiplexed protein detection and quantification. Mol. Cell. Proteom. 20, 100155 (2021). https:\/\/doi.org\/10.1016\/j.mcpro.2021.100155.","journal-title":"Mol. Cell. Proteom."},{"issue":"no. 4","key":"4302_CR30","doi-asserted-by":"publisher","first-page":"bqab032","DOI":"10.1210\/endocr\/bqab032","volume":"162","author":"ER Barros","year":"2021","unstructured":"E.R. Barros et al., Proteomic profile of urinary extracellular vesicles identifies AGP1 as a potential biomarker of primary aldosteronism. Endocrinology 162(no. 4), bqab032 (2021). https:\/\/doi.org\/10.1210\/endocr\/bqab032.","journal-title":"Endocrinology"},{"key":"4302_CR31","doi-asserted-by":"publisher","first-page":"1096441","DOI":"10.3389\/fendo.2023.1096441","volume":"14","author":"L Bertolone","year":"2023","unstructured":"L. Bertolone et al., Proteomic analysis of urinary extracellular vesicles highlights specific signatures for patients with primary aldosteronism. Front. Endocrinol. 14, 1096441 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1096441.","journal-title":"Front. Endocrinol."},{"issue":"no. 5","key":"4302_CR32","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/HYPERTENSIONAHA.121.16498","volume":"79","author":"UI Scholl","year":"2022","unstructured":"U.I. Scholl, Genetics of primary aldosteronism. Hypertension 79(no. 5), 887\u2013897 (2022). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.16498.","journal-title":"Hypertension"},{"issue":"no. 6","key":"4302_CR33","doi-asserted-by":"publisher","first-page":"C5","DOI":"10.1530\/EJE-22-0123","volume":"186","author":"M Reincke","year":"2022","unstructured":"M. Reincke, T.A. Williams, True unilateral primary aldosteronism exists, and unilateral adrenalectomy saves lives. Eur. J. Endocrinol. 186(no. 6), C5\u2013C7 (2022). https:\/\/doi.org\/10.1530\/EJE-22-0123.","journal-title":"Eur. J. Endocrinol."},{"issue":"no. 6","key":"4302_CR34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.surg.2012.08.042","volume":"152","author":"M Iacobone","year":"2012","unstructured":"M. Iacobone et al., Unilateral adrenal hyperplasia: A novel cause of surgically correctable primary hyperaldosteronism. Surgery 152(no. 6), 1248\u20131255 (2012). https:\/\/doi.org\/10.1016\/j.surg.2012.08.042.","journal-title":"Surgery"},{"issue":"no. 1","key":"4302_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","volume":"106","author":"TA Williams","year":"2021","unstructured":"T.A. Williams et al., International histopathology consensus for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 106(no. 1), 42\u201354 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa484.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"no. 6","key":"4302_CR36","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1530\/EJE-22-0375","volume":"187","author":"S-Y Chen","year":"2022","unstructured":"S.-Y. Chen et al., Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur. J. Endocrinol. 187(no. 6), S47\u2013S58 (2022). https:\/\/doi.org\/10.1530\/EJE-22-0375.","journal-title":"Eur. J. Endocrinol."},{"issue":"no. 9","key":"4302_CR37","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/jcdd9090300","volume":"9","author":"N Qian","year":"2022","unstructured":"N. Qian, J. Xu, Y. Wang, Stroke risks in primary aldosteronism with different treatments: a systematic review and meta-analysis. J. Cardiovasc. Dev. Dis. 9(no. 9), 300 (2022). https:\/\/doi.org\/10.3390\/jcdd9090300.","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"no. 1","key":"4302_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6(no. 1), 51\u201359 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30367-4.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"no. 1","key":"4302_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/endrev\/bnad024","volume":"45","author":"GL Hundemer","year":"2024","unstructured":"G.L. Hundemer, A.A. Leung, G.A. Kline, J.M. Brown, A.F. Turcu, A. Vaidya, Biomarkers to guide medical therapy in primary aldosteronism. Endocr. Rev. 45(no. 1), 69\u201394 (2024). https:\/\/doi.org\/10.1210\/endrev\/bnad024.","journal-title":"Endocr. Rev."},{"issue":"no. 2","key":"4302_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","volume":"13","author":"J Yang","year":"2025","unstructured":"J. Yang et al., Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. Lancet Diabetes Endocrinol. 13(no. 2), 119\u2013133 (2025). https:\/\/doi.org\/10.1016\/S2213-8587(24)00308-5.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"no. 8","key":"4302_CR41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/ecco-jcc\/jjac033","volume":"16","author":"JK Nowak","year":"2022","unstructured":"J.K. Nowak et al., Characterisation of the circulating transcriptomic landscape in inflammatory bowel disease provides evidence for dysregulation of multiple transcription factors including NFE2, SPI1, CEBPB, and IRF2. J. Crohns Colitis 16(no. 8), 1255\u20131268 (2022). https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac033.","journal-title":"J. Crohns Colitis"},{"issue":"no. 2","key":"4302_CR42","doi-asserted-by":"publisher","first-page":"e14603","DOI":"10.1111\/cns.14603","volume":"30","author":"Z Tian","year":"2024","unstructured":"Z. Tian, X. Wu, B. Zhang, W. Li, C. Wang, Transcription factor CEBPB mediates intracranial aneurysm rupture by inflammatory and immune response. CNS Neurosci. Ther. 30(no. 2), e14603 (2024). https:\/\/doi.org\/10.1111\/cns.14603.","journal-title":"CNS Neurosci. Ther."},{"issue":"no. 10","key":"4302_CR43","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/genes10100802","volume":"10","author":"Y-P Liu","year":"2019","unstructured":"Y.-P. Liu et al., Transcription factor CEBPB inhibits the expression of the human HTR1A by binding to 5\u2032 regulatory region in vitro. Genes 10(no. 10), 802 (2019). https:\/\/doi.org\/10.3390\/genes10100802.","journal-title":"Genes"},{"key":"4302_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coemr.2019.07.003","volume":"8","author":"E Louiset","year":"2019","unstructured":"E. Louiset, C. Duparc, H. Lefebvre, Role of serotonin in the paracrine control of adrenal steroidogenesis in physiological and pathophysiological conditions. Curr. Opin. Endocr. Metab. Res. 8, 50\u201359 (2019). https:\/\/doi.org\/10.1016\/j.coemr.2019.07.003.","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"issue":"no. 3","key":"4302_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/hae.14300","volume":"27","author":"DM Mann","year":"2021","unstructured":"D.M. Mann, K.A. Stafford, M. Poon, D. Matino, D.W. Stafford, The Function of extravascular coagulation factor IX in haemostasis. Haemophilia 27(no. 3), 332\u2013339 (2021). https:\/\/doi.org\/10.1111\/hae.14300.","journal-title":"Haemophilia"},{"issue":"no. 10","key":"4302_CR46","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cbin.10491","volume":"39","author":"H Kitano","year":"2015","unstructured":"H. Kitano, A. Mamiya, I. Tomomi, K. Shinichiro, H. Chiaki, Coagulation factor IX regulates cell migration and adhesion in vitro. Cell Biol. Int. 39(no. 10), 1162\u20131172 (2015). https:\/\/doi.org\/10.1002\/cbin.10491.","journal-title":"Cell Biol. Int."},{"issue":"no. 9381","key":"4302_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(03)14021-4","volume":"362","author":"A \u0160r\u00e1mek","year":"2003","unstructured":"A. \u0160r\u00e1mek, M. Kriek, F. Rosendaal, Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 362(no. 9381), 351\u2013354 (2003). https:\/\/doi.org\/10.1016\/S0140-6736(03)14021-4.","journal-title":"Lancet"},{"key":"4302_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/3889419","volume":"2022","author":"K Chen","year":"2022","unstructured":"K. Chen et al., HSPB1 regulates autophagy and apoptosis in vascular smooth muscle cells in arteriosclerosis obliterans. Cardiovasc. Ther. 2022, 1\u201311 (2022). https:\/\/doi.org\/10.1155\/2022\/3889419.","journal-title":"Cardiovasc. Ther."},{"key":"4302_CR49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fimmu.2016.00285","volume":"7","author":"Z Batulan","year":"2016","unstructured":"Z. Batulan et al., Extracellular release and signaling by heat shock protein 27: role in modifying vascular inflammation. Front. Immunol. 7, 285 (2016). https:\/\/doi.org\/10.3389\/fimmu.2016.00285.","journal-title":"Front. Immunol."},{"issue":"no. 6","key":"4302_CR50","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1210\/clinem\/dgab078","volume":"106","author":"KM Love","year":"2021","unstructured":"K.M. Love, Z. Liu, DPP4 activity, hyperinsulinemia, and atherosclerosis. J. Clin. Endocrinol. Metab. 106(no. 6), 1553\u20131565 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab078.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"no. 3","key":"4302_CR51","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00180-020-00999-9","volume":"36","author":"BG Marcot","year":"2021","unstructured":"B.G. Marcot, A.M. Hanea, What is an optimal value of k in k-fold cross-validation in discrete Bayesian network analysis?. Comput. Stat. 36(no. 3), 2009\u20132031 (2021). https:\/\/doi.org\/10.1007\/s00180-020-00999-9.","journal-title":"Comput. Stat."},{"key":"4302_CR52","volume-title":"Statistical data analysis: a practical guide","author":"M Meloun","year":"2012","unstructured":"M. Meloun, J. Militk\u00fd, in Statistical data analysis: a practical guide (WPI, Woodhead Publ. India Pvt. Ltd, New Delhi, 2012), Reprinted. in Woodhead Publishing India in materials."},{"key":"4302_CR53","volume-title":"Speech and language processing","author":"D Jurafsky","year":"2014","unstructured":"D. Jurafsky, J.H. Martin, in Speech and language processing (Pearson Education, Harlow, 2014), 2. ed."},{"issue":"no. 1","key":"4302_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/24754269.2021.1980261","volume":"6","author":"F Sohil","year":"2022","unstructured":"F. Sohil, M.U. Sohali, J. Shabbir, An introduction to statistical learning with applications in R: by Gareth James, Daniela Witten, Trevor Hastie, and Robert Tibshirani, New York, Springer Science and Business Media, 2013, $41.98, eISBN: 978-1-4614-7137-7. Stat. Theory Relat. Fields 6(no. 1), 87\u201387 (2022). https:\/\/doi.org\/10.1080\/24754269.2021.1980261.","journal-title":"Stat. Theory Relat. Fields"},{"key":"4302_CR55","unstructured":"A.Y. Ng, M.I. Jordan, in Proceedings of the 15th International Conference on Neural Information Processing Systems: Natural and Synthetic, in NIPS\u201901 (MIT Press, Cambridge, MA, USA, 2001), pp. 841\u2013848On discriminative vs. generative classifiers: a comparison of logistic regression and naive Bayes."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04302-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:11:59Z","timestamp":1755774719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04302-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4302"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04302-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants whose samples were included in the study. The study was approved by the Swedish Ethical Review Authority, with grant registry number 2020-06379, date 2020-12-16; and 2021-03188, date 2021-07-15). Data protection laws were adhered to.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}